Cargando…

Concomitant Acute Hepatic Failure and Renal Failure Induced by Intravenous Amiodarone: A Case Report and Literature Review

Hepatotoxicity caused by chronic oral amiodarone is well documented with around 15-20% incidence rate. However, acute liver failure due to intravenous (IV) amiodarone is rare clinical presentation with 3% incidence rate. Incidence of concomitant renal failure is even rarer. There is no full explanat...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed, Mujtaba, Al-Hillan, Alsadiq, Flores, Marcus, Kaunzinger, Christian, Mushtaq, Arman, Asif, Arif, Hossain, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011916/
https://www.ncbi.nlm.nih.gov/pubmed/32095172
http://dx.doi.org/10.14740/gr1254
_version_ 1783496154037616640
author Mohamed, Mujtaba
Al-Hillan, Alsadiq
Flores, Marcus
Kaunzinger, Christian
Mushtaq, Arman
Asif, Arif
Hossain, Mohammad
author_facet Mohamed, Mujtaba
Al-Hillan, Alsadiq
Flores, Marcus
Kaunzinger, Christian
Mushtaq, Arman
Asif, Arif
Hossain, Mohammad
author_sort Mohamed, Mujtaba
collection PubMed
description Hepatotoxicity caused by chronic oral amiodarone is well documented with around 15-20% incidence rate. However, acute liver failure due to intravenous (IV) amiodarone is rare clinical presentation with 3% incidence rate. Incidence of concomitant renal failure is even rarer. There is no full explanation for the underlying mechanism. Herein, we are presenting a rare case of concomitant acute hepatic failure and acute-on-chronic renal injury induced by use of IV amiodarone. A 67-year-old man with past medical history of coronary artery disease s/p coronary artery bypass graft (CABG), history of alcoholism, and chronic kidney disease stage 3 presented with chest pain for 1 week. In the emergency department (ED), he was found to have atrial flutter. Due to unresponsiveness to IV β-blocker and diltiazem, the patient was loaded with IV amiodarone and continued IV amiodarone drip. His liver function tests (LFTs) and renal functions at the time of administration of IV amiodarone were aspartate transaminase (AST) 176 (10 - 42 IU/L) and alanine transaminase (ALT) 208 (10 - 60 IU/L), international normalized ratio (INR) 1.39 (reference value 2 - 3), blood urea nitrogen (BUN) 37 (5 - 25 mg/dL), and creatinine 1.85. Sixteen hours later patient developed acute hepatic failure with AST 4,250 (reference value 10 - 42 IU/L), ALT 2,422 (10 - 60 IU/L), INR 2.28, and acute renal failure with creatinine of 3.2 mg/dL (0.44 - 1.0 mg/dL), and BUN of 44 mg/d (5 - 25 mg/dL). Patient was intubated due to acute hepatic encephalopathy and sent to intensive care unit (ICU). IV amiodarone was stopped immediately. All workup for other causes of acute hepatic failure came back negative. He was started on IV N-acetylcysteine and required hemodialysis for acute-on-chronic renal failure. LFTs peaked 72 h after discontinuation of amiodarone. Kidney functions started to improve 5 days after discontinuation of amiodarone and patient came off hemodialysis. Acute hepatic failure as result of IV amiodarone is a rare presentation; however, it has a high mortality. Risk factors include low ejection fraction, hepatic congestion and pre-existing hepatic dysfunction. No obvious underlying mechanism to this presentation has been fully explained. Acute renal failure can be associated with this presentation which is even rarer. Stopping IV amiodarone, administering N-acetylcysteine and good supportive care can lead to favorable outcome.
format Online
Article
Text
id pubmed-7011916
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-70119162020-02-24 Concomitant Acute Hepatic Failure and Renal Failure Induced by Intravenous Amiodarone: A Case Report and Literature Review Mohamed, Mujtaba Al-Hillan, Alsadiq Flores, Marcus Kaunzinger, Christian Mushtaq, Arman Asif, Arif Hossain, Mohammad Gastroenterology Res Case Report Hepatotoxicity caused by chronic oral amiodarone is well documented with around 15-20% incidence rate. However, acute liver failure due to intravenous (IV) amiodarone is rare clinical presentation with 3% incidence rate. Incidence of concomitant renal failure is even rarer. There is no full explanation for the underlying mechanism. Herein, we are presenting a rare case of concomitant acute hepatic failure and acute-on-chronic renal injury induced by use of IV amiodarone. A 67-year-old man with past medical history of coronary artery disease s/p coronary artery bypass graft (CABG), history of alcoholism, and chronic kidney disease stage 3 presented with chest pain for 1 week. In the emergency department (ED), he was found to have atrial flutter. Due to unresponsiveness to IV β-blocker and diltiazem, the patient was loaded with IV amiodarone and continued IV amiodarone drip. His liver function tests (LFTs) and renal functions at the time of administration of IV amiodarone were aspartate transaminase (AST) 176 (10 - 42 IU/L) and alanine transaminase (ALT) 208 (10 - 60 IU/L), international normalized ratio (INR) 1.39 (reference value 2 - 3), blood urea nitrogen (BUN) 37 (5 - 25 mg/dL), and creatinine 1.85. Sixteen hours later patient developed acute hepatic failure with AST 4,250 (reference value 10 - 42 IU/L), ALT 2,422 (10 - 60 IU/L), INR 2.28, and acute renal failure with creatinine of 3.2 mg/dL (0.44 - 1.0 mg/dL), and BUN of 44 mg/d (5 - 25 mg/dL). Patient was intubated due to acute hepatic encephalopathy and sent to intensive care unit (ICU). IV amiodarone was stopped immediately. All workup for other causes of acute hepatic failure came back negative. He was started on IV N-acetylcysteine and required hemodialysis for acute-on-chronic renal failure. LFTs peaked 72 h after discontinuation of amiodarone. Kidney functions started to improve 5 days after discontinuation of amiodarone and patient came off hemodialysis. Acute hepatic failure as result of IV amiodarone is a rare presentation; however, it has a high mortality. Risk factors include low ejection fraction, hepatic congestion and pre-existing hepatic dysfunction. No obvious underlying mechanism to this presentation has been fully explained. Acute renal failure can be associated with this presentation which is even rarer. Stopping IV amiodarone, administering N-acetylcysteine and good supportive care can lead to favorable outcome. Elmer Press 2020-02 2020-02-01 /pmc/articles/PMC7011916/ /pubmed/32095172 http://dx.doi.org/10.14740/gr1254 Text en Copyright 2020, Mohamed et al. http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Mohamed, Mujtaba
Al-Hillan, Alsadiq
Flores, Marcus
Kaunzinger, Christian
Mushtaq, Arman
Asif, Arif
Hossain, Mohammad
Concomitant Acute Hepatic Failure and Renal Failure Induced by Intravenous Amiodarone: A Case Report and Literature Review
title Concomitant Acute Hepatic Failure and Renal Failure Induced by Intravenous Amiodarone: A Case Report and Literature Review
title_full Concomitant Acute Hepatic Failure and Renal Failure Induced by Intravenous Amiodarone: A Case Report and Literature Review
title_fullStr Concomitant Acute Hepatic Failure and Renal Failure Induced by Intravenous Amiodarone: A Case Report and Literature Review
title_full_unstemmed Concomitant Acute Hepatic Failure and Renal Failure Induced by Intravenous Amiodarone: A Case Report and Literature Review
title_short Concomitant Acute Hepatic Failure and Renal Failure Induced by Intravenous Amiodarone: A Case Report and Literature Review
title_sort concomitant acute hepatic failure and renal failure induced by intravenous amiodarone: a case report and literature review
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011916/
https://www.ncbi.nlm.nih.gov/pubmed/32095172
http://dx.doi.org/10.14740/gr1254
work_keys_str_mv AT mohamedmujtaba concomitantacutehepaticfailureandrenalfailureinducedbyintravenousamiodaroneacasereportandliteraturereview
AT alhillanalsadiq concomitantacutehepaticfailureandrenalfailureinducedbyintravenousamiodaroneacasereportandliteraturereview
AT floresmarcus concomitantacutehepaticfailureandrenalfailureinducedbyintravenousamiodaroneacasereportandliteraturereview
AT kaunzingerchristian concomitantacutehepaticfailureandrenalfailureinducedbyintravenousamiodaroneacasereportandliteraturereview
AT mushtaqarman concomitantacutehepaticfailureandrenalfailureinducedbyintravenousamiodaroneacasereportandliteraturereview
AT asifarif concomitantacutehepaticfailureandrenalfailureinducedbyintravenousamiodaroneacasereportandliteraturereview
AT hossainmohammad concomitantacutehepaticfailureandrenalfailureinducedbyintravenousamiodaroneacasereportandliteraturereview